Related Experiment Video
Updated: Jun 12, 2026
07:54
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Heterogeneity-based stratification identifies CKMT2 as a prognostic marker in osteosarcoma.
Xuesong Li1, Guanghao Li2, Tianchou Peng3
1Department of Pediatric Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.
Frontiers in Cell and Developmental Biology
|June 11, 2026
Summary
This study maps osteosarcoma intratumoral heterogeneity (ITH), revealing distinct molecular subtypes linked to prognosis. Creatine Kinase Mitochondrial 2 (CKMT2) is identified as a key driver and therapeutic target for osteosarcoma.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Osteosarcoma (OS) is the most common primary bone cancer.
- Intratumoral heterogeneity (ITH) in OS contributes to treatment resistance and metastasis.
- The molecular drivers and clinical impact of OS ITH are not well understood.
Purpose of the Study:
- To systematically map the ITH landscape of osteosarcoma.
- To identify molecular subtypes and their clinical relevance.
- To discover novel therapeutic targets for osteosarcoma.
Main Methods:
- Integrated single-cell and multi-cohort transcriptomic data.
- Inferred copy number variation (CNV) to identify malignant cells.
- Applied machine learning for prognostic modeling and target identification.
Main Results:
- Identified ten cell types and five malignant subtypes within OS, stratifying ITH levels.
- Discovered two distinct molecular subtypes correlating with prognosis and immune infiltration.
- Validated Creatine Kinase Mitochondrial 2 (CKMT2) as a prognostic biomarker and therapeutic target.
Conclusions:
- Osteosarcoma exhibits significant ITH with distinct molecular subtypes impacting clinical outcomes.
- CKMT2 plays a crucial role in osteosarcoma progression and represents a viable therapeutic target.